Author
@FierceBiotech FierceBiotech
Biotech trade-press outlet breaking trial, deal, and FDA news with clinical context
Report original biotech/pharma industry news — clinical read
trader score
+1.04
hit rate
67%
mean α
+0.32%
signals 14d
6
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 18 scored bets: 67% hit rate, +0.32% mean alpha, trader score +1.04.
Recent signals6receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-08-28 | · | @FierceBiotech | · | Reports emerging tRNA therapeutic potential for treating genetic disease. | · | tweet ↗ |
| 2026-08-28 | · | @FierceBiotech | · | Reports Genentech entering a $1B pact with DualityBio targeting ADC-resistant cancers. | · | tweet ↗ |
| 2026-08-27 | · | @FierceBiotech | · | UCSF scientists suggest protein interactions may reveal druggable autism targets. | · | tweet ↗ |
| 2026-08-25 | · | @FierceBiotech | · | FDA extended review of Capricor's DMD candidate after a negative advisory vote. | · | tweet ↗ |
| 2026-08-18 | · | @FierceBiotech | · | BioMarin acquires Alesta for $275 million to expand its bone-disease unit. | · | tweet ↗ |
| 2026-08-18 | · | @FierceBiotech | · | Amylyx's avexitide reportedly halved dangerous blood-sugar crashes. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.